Global pharma major Lupin Limited (Lupin) announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for empagliflozin, linagliptin and metformin hydrochloride extended-release (ER) tablets, 5 mg/2.5 mg/1,000 mg, 10 mg/5 mg/1,000 mg, 12.5 mg/2.5 mg/1,000 mg, and 25 mg/5 mg/1,000 mg, to market a generic equivalent of Trijardy XR tablets, 5 mg/2.5 mg/1,000 mg, 10 mg/5 mg/1,000 mg, 12.5 mg/2.5 mg/1,000 mg, and 25 mg/5 mg/1,000 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. This product will be manufactured at Lupin’s Pithampur facility in India.
Lupin Pharm`s Generic Empagliflozin Receives Tentative Approval in US
Eli Lilly has announced that its net income on a reported basis rose to $2.24bn for the first quarter (Q1) of 2024, a 67% increase from $1.34bn in the same period of the previous year.
Lilly’s growth drivers, Verzenio and Jardiance, suffer setbacks
Prinston Pharma`s Generic Empagliflozin Receives Tentative Approval in U.S
Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo.Statistical...
Inventiva to present the results of LEGEND Phase IIa combination trial
??Boehringer's Jardiance now gets CDSCO nod for chronic kidney disease
Boehringer`s aldosterone synthase inhibitor shows promise in CKD trial